Alexander W. Hird, Ph.D.
Affiliations: | 2006 | Boston College, Newton, MA, United States |
Area:
catalystsGoogle:
"Alexander Hird"Mean distance: 8.07 | S | N | B | C | P |
Parents
Sign in to add mentor| Amir H. Hoveyda | grad student | 2006 | Boston College | |
| (New methods for catalytic enantioselective conjugate addition of dialkylzinc reagents to alpha,beta-unsaturated carbonyls: Discovery and use of new catalysts.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Maia de Oliveira T, Korboukh V, Caswell S, et al. (2020) The structure of human GCN2 reveals a parallel, back-to-back kinase dimer with a plastic DFG activation loop motif. The Biochemical Journal. 477: 275-284 |
| Yang B, Hird AW, Bodnarchuk MS, et al. (2019) Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254). Bioorganic & Medicinal Chemistry. 115227 |
| Balazs AYS, Carbajo RJ, Davies NL, et al. (2019) Free Ligand 1D NMR Conformational Signatures to Enhance Structure Based Drug Design of a Mcl-1 inhibitor (AZD5991) and other Synthetic Macrocycles. Journal of Medicinal Chemistry |
| Hird AW, Tron AE. (2019) Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacology & Therapeutics |
| Tron AE, Belmonte MA, Adam A, et al. (2018) Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications. 9: 5341 |
| Yang B, Vasbinder M, Hird AW, et al. (2018) Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. Journal of Medicinal Chemistry |
| Tron AE, Belmonte MA, Criscione S, et al. (2018) Abstract 302: Selective Mcl-1 inhibition by AZD5991 induces on-target cell death and achieves antitumor activity in multiple myeloma and acute myeloid leukemia Cancer Research. 78: 302-302 |
| Barlaam B, Savi CD, Drew L, et al. (2018) Abstract 1650: Discovery of AZD4573, a potent and selective inhibitor of CDK9 that enables transient target engagement for the treatment of hematologic malignancies Cancer Research. 78: 1650-1650 |
| Johannes JW, Bates S, Beigie C, et al. (2017) Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors". Acs Medicinal Chemistry Letters. 8: 1204 |
| Johannes JW, Bates S, Beigie C, et al. (2017) Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. Acs Medicinal Chemistry Letters. 8: 239-244 |